Ensign Peak Advisors
GILD icon

Ensign Peak Advisors’s Gilead Sciences GILD Stock Holding History

Ensign Peak Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245M Sell
1,940,617
-397,605
-17% -$52.4M 0.4% 45
2026
Q1 		$326M Buy
2,338,222
+401,853
+21% +$56.3M 0.61% 26
2025
Q4 		$238M Sell
1,936,369
-721,043
-27% -$87.6M 0.42% 45
2025
Q3 		$295M Buy
2,657,412
+359,710
+16% +$40.9M 0.48% 39
2025
Q2 		$255M Buy
2,297,702
+152,685
+7% +$16.2M 0.44% 46
2025
Q1 		$240M Buy
2,145,017
+475,146
+28% +$49M 0.46% 44
2024
Q4 		$154M Buy
1,669,871
+60,474
+4% +$5.44M 0.27% 73
2024
Q3 		$135M Buy
1,609,397
+180,559
+13% +$13.8M 0.24% 87
2024
Q2 		$98M Sell
1,428,838
-4,940
-0.3% -$330K 0.18% 104
2024
Q1 		$105M Sell
1,433,778
-1,545,570
-52% -$119M 0.19% 106
2023
Q4 		$241M Sell
2,979,348
-599,352
-17% -$46.6M 0.48% 48
2023
Q3 		$268M Sell
3,578,700
-62,976
-2% -$4.84M 0.57% 38
2023
Q2 		$281M Buy
3,641,676
+66,002
+2% +$5.26M 0.57% 37
2023
Q1 		$297M Sell
3,575,674
-384,720
-10% -$31.9M 0.64% 34
2022
Q4 		$340M Sell
3,960,394
-524,375
-12% -$41.5M 0.77% 27
2022
Q3 		$277M Buy
4,484,769
+1,790,559
+66% +$113M 0.69% 35
2022
Q2 		$167M Buy
2,694,210
+489,240
+22% +$30.3M 0.4% 69
2022
Q1 		$131M Buy
2,204,970
+650,488
+42% +$41.6M 0.27% 88
2021
Q4 		$113M Sell
1,554,482
-432,547
-22% -$29.8M 0.22% 103
2021
Q3 		$139M Sell
1,987,029
-132,383
-6% -$9.3M 0.29% 89
2021
Q2 		$146M Buy
2,119,412
+272,079
+15% +$18.2M 0.29% 89
2021
Q1 		$119M Buy
1,847,333
+271,021
+17% +$17.5M 0.26% 98
2020
Q4 		$91.8M Buy
1,576,312
+519,718
+49% +$31.4M 0.21% 112
2020
Q3 		$66.8M Sell
1,056,594
-197,800
-16% -$13.7M 0.17% 116
2020
Q2 		$96.5M Sell
1,254,394
-244,281
-16% -$18.7M 0.26% 78
2020
Q1 		$112M Buy
1,498,675
+623,260
+71% +$43.1M 0.38% 62
2019
Q4 		$56.9M Buy
+875,415
New +$57M 0.15% 115

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ensign Peak Advisors's GILD Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Gilead Sciences (GILD) stake by 17% in Q2 2026, selling an estimated $52.4M and leaving 1,940,617 shares worth $245M. The position accounts for 0.4% of the portfolio, ranked #45.

Ensign Peak Advisors first reported a position in GILD in Q4 2019 and has held it in 27 quarters since. The position peaked at $340M in Q4 2022. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Ensign Peak Advisors held 1,940,617 shares of Gilead Sciences worth $245M as of Q2 2026.
  • Ensign Peak Advisors sold 397,605 Gilead Sciences shares in Q2 2026, an estimated $52.4M.
  • Gilead Sciences made up 0.4% of Ensign Peak Advisors's portfolio in Q2 2026, its #45 holding.
  • Ensign Peak Advisors first reported a position in Gilead Sciences in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Gilead Sciences position peaked at $340M in Q4 2022.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.